Latest News
Palvella Therapeutics, Inc.
- Form 144 PALVELLA THERAPEUTICS For: 21 October
- Palvella at Chardan conference: rare-disease push nears launch By Investing.com
- Palvella Therapeutics stock rating reiterated at Buy by H.C. Wainwright
- Why is Palvella Therapeutics stock sliding 3% today?
- Palvella to present pediatric data on rapamycin gel at PeDRA By Investing.com
- Palvella Therapeutics to Present Phase 3 SELVA and Phase 2
- Palvella Therapeutics director George M. Jenkins disposes of $3.58m PVLA stock
- Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
- Palvella Therapeutics Announces Three Poster Presentations
- Palvella presents data on rapamycin gel, DSAP patient analysis
- Palvella lands third FDA grant year for QTORIN rapamycin after Phase 3 win
- Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger (NASDAQ:PVLA)
Headlines from the last 30 days, linking to the original publishers. See all market news →